On October 22, 2019 Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs of patients with life-threatening hematologic cancers, reported that it will release its financial results for the second quarter ended September 30, 2019 on Tuesday, November 5, 2019 after the close of the market (Press release, Aptose Biosciences, OCT 22, 2019, View Source [SID1234542400]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Conference Call & Webcast:
Tuesday, November 5th @ 5:00pm Eastern Time
Toll-Free: 1-844-882-7834
International/Toll: 1-574-990-9707
Passcode: 8417047
Webcast: (Link)
Replays available through November 12, 2019
Toll-Free: 1-855-859-2056
International/Toll: 1-404-537-3406
Replay Passcode: 8417047
The live conference call can also be accessed through a link on the Investor Relations section of Aptose’s website at ir.aptose.com. Please log onto the webcast at least 10 minutes prior to the start of the call to ensure time for any software downloads that may be required. An archived version of the webcast along with a transcript will be available on the company’s website for 30 days.
The press release, the financial statements and the management’s discussion and analysis for the quarter ended September 30, 2019 will be available on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml